Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
Dermata Therapeutics (DRMA) Projected to Post Earnings on Monday
Dermata Opens a New Chapter with the Release of Tome Skincare
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Dermata to Present on BioPub on January 31, 2025
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Dermata to Present at the Emerging Growth Conference on April 3, 2024
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
Dermata to Present at the Emerging Growth Conference on February 7, 2024
Why Is Dermata Therapeutics (DRMA) Stock Up 62% Today?
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne